David A. Siegel Adaptive Biotechnologies Corp Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q4 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Adaptive Biotechnologies Corp stock. As of the latest transaction made, Two Sigma Advisers, LP holds 51,600 shares of ADPT stock, worth $431,891. This represents 0.0% of its overall portfolio holdings.

Number of Shares

51,600

Previous 10,400 396.15%

Holding current value

$431,891

Previous $53,000 483.02%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$4.37 - $6.78 $180,044 - $279,336	41,200 Added 396.15%	51,600 $309,000
Q3 2024 Nov 14, 2024	BUY	$3.37 - $5.12 $35,048 - $53,248	10,400 New	10,400 $53,000
Q1 2024 May 15, 2024	BUY	$2.88 - $4.8 $2,304 - $3,840	800 Added 8.0%	10,800 $34,000
Q4 2023 Feb 14, 2024	BUY	$3.46 - $5.33 $34,600 - $53,300	10,000 New	10,000 $49,000
Q2 2023 Aug 14, 2023	SELL	$6.19 - $8.78 $6,809 - $9,658	-1,100 Reduced 6.92%	14,800 $99,000
Q1 2023 May 15, 2023	SELL	$7.8 - $10.11 $154,440 - $200,178	-19,800 Reduced 55.46%	15,900 $140,000
Q4 2022 Feb 14, 2023	SELL	$6.26 - $9.34 $96,404 - $143,836	-15,400 Reduced 30.14%	35,700 $272,000
Q3 2022 Nov 14, 2022	BUY	$6.5 - $12.67 $30,550 - $59,549	4,700 Added 10.13%	51,100 $364,000
Q2 2022 Aug 15, 2022	BUY	$6.4 - $14.73 $219,520 - $505,239	34,300 Added 283.47%	46,400 $375,000
Q1 2022 May 16, 2022	BUY	$10.12 - $28.9 $122,451 - $349,690	12,100 New	12,100 $168,000
Q2 2021 Aug 16, 2021	SELL	$32.22 - $44.59 $1.15 Million - $1.59 Million	-35,600 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$37.26 - $67.74 $1.33 Million - $2.41 Million	35,600 New	35,600 $1.43 Million

Others Institutions Holding ADPT

# of Institutions

225

Shares Held

146M

Call Options Held

19.6K

Put Options Held

27.2K

View Full List

About Adaptive Biotechnologies Corp

Ticker ADPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 142,872,992
Market Cap $1.2B
Description
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...

More about ADPT

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account